Cytopathological alterations and therapeutic approaches in Binswanger's disease

I. Akiguchi, H. Tomimoto, H. Wakita, Y. Yamamoto, T. Suenaga, M. Ueno, H. Budka

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Binswanger's disease (BD) is a condition characterized by prominent brain atrophy with ventricular dilatation, diffuse white matter (WM) lesions and a scattering of lacunar infarcts. BD patients have dementia, and have vascular risk factors, focal cerebrovascular deficits and evidence of subcortical cerebral dysfunction. From our clinical studies, the most effective prophylaxis against the development of BD is to manage the hypertension, especially a high nocturnal blood pressure, in the early stage patients showing only a scattering of lacunes and/or mild WM lesions. The pathogenesis of BD is likely to be chronic cerebral ischemia due to hypertensive small artery disease with capillary collagenosis, which causes the multiple lacunes and the alterations in the glia and axons. In addition, arterial hypertension and a subsequent dysfunction of the blood-brain barrier (BBB) may cause the WM lesions. A compromised BBB will permit the entry of serum components, immunoglobulins, complements and fibrinogen into the perivascular neural parenchyma. These substances may subsequently activate both astro- and microglia and thus damage the myelin structures. Experimentally, immunosuppressants, cyclosporin A and FK 506 suppressed both the glial activation and WM changes after chronic cerebral hypoperfusion. The prothrombotic state of the microcirculation in BD patients may also contribute to local inflammation and the BBB dysfunction, because thrombin and prostanoids are involved in various tissue reactions including brain edema and glial activation. Therefore, novel therapeutic approaches using the administration of anti-thrombin and cyclo-oxygenase-2 inhibitors as well as immunosuppressants may be useful for preventing the progression of BD.

Original languageEnglish
Pages (from-to)119-128
Number of pages10
JournalNeuropathology
Volume19
Issue number1
DOIs
Publication statusPublished - 08-03-1999
Externally publishedYes

Fingerprint

Vascular Dementia
Blood-Brain Barrier
Neuroglia
Immunosuppressive Agents
Hypertension
Thrombin
Therapeutics
Lacunar Stroke
Cyclooxygenase Inhibitors
Brain Edema
Microglia
Tacrolimus
Microcirculation
Myelin Sheath
Brain Ischemia
Astrocytes
Fibrinogen
Cyclosporine
Prostaglandins
Atrophy

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Akiguchi, I., Tomimoto, H., Wakita, H., Yamamoto, Y., Suenaga, T., Ueno, M., & Budka, H. (1999). Cytopathological alterations and therapeutic approaches in Binswanger's disease. Neuropathology, 19(1), 119-128. https://doi.org/10.1046/j.1440-1789.1999.00208.x
Akiguchi, I. ; Tomimoto, H. ; Wakita, H. ; Yamamoto, Y. ; Suenaga, T. ; Ueno, M. ; Budka, H. / Cytopathological alterations and therapeutic approaches in Binswanger's disease. In: Neuropathology. 1999 ; Vol. 19, No. 1. pp. 119-128.
@article{22996ade1e4947a0ba9f7b7bfc022d67,
title = "Cytopathological alterations and therapeutic approaches in Binswanger's disease",
abstract = "Binswanger's disease (BD) is a condition characterized by prominent brain atrophy with ventricular dilatation, diffuse white matter (WM) lesions and a scattering of lacunar infarcts. BD patients have dementia, and have vascular risk factors, focal cerebrovascular deficits and evidence of subcortical cerebral dysfunction. From our clinical studies, the most effective prophylaxis against the development of BD is to manage the hypertension, especially a high nocturnal blood pressure, in the early stage patients showing only a scattering of lacunes and/or mild WM lesions. The pathogenesis of BD is likely to be chronic cerebral ischemia due to hypertensive small artery disease with capillary collagenosis, which causes the multiple lacunes and the alterations in the glia and axons. In addition, arterial hypertension and a subsequent dysfunction of the blood-brain barrier (BBB) may cause the WM lesions. A compromised BBB will permit the entry of serum components, immunoglobulins, complements and fibrinogen into the perivascular neural parenchyma. These substances may subsequently activate both astro- and microglia and thus damage the myelin structures. Experimentally, immunosuppressants, cyclosporin A and FK 506 suppressed both the glial activation and WM changes after chronic cerebral hypoperfusion. The prothrombotic state of the microcirculation in BD patients may also contribute to local inflammation and the BBB dysfunction, because thrombin and prostanoids are involved in various tissue reactions including brain edema and glial activation. Therefore, novel therapeutic approaches using the administration of anti-thrombin and cyclo-oxygenase-2 inhibitors as well as immunosuppressants may be useful for preventing the progression of BD.",
author = "I. Akiguchi and H. Tomimoto and H. Wakita and Y. Yamamoto and T. Suenaga and M. Ueno and H. Budka",
year = "1999",
month = "3",
day = "8",
doi = "10.1046/j.1440-1789.1999.00208.x",
language = "English",
volume = "19",
pages = "119--128",
journal = "Neuropathology",
issn = "0919-6544",
publisher = "Wiley-Blackwell",
number = "1",

}

Akiguchi, I, Tomimoto, H, Wakita, H, Yamamoto, Y, Suenaga, T, Ueno, M & Budka, H 1999, 'Cytopathological alterations and therapeutic approaches in Binswanger's disease', Neuropathology, vol. 19, no. 1, pp. 119-128. https://doi.org/10.1046/j.1440-1789.1999.00208.x

Cytopathological alterations and therapeutic approaches in Binswanger's disease. / Akiguchi, I.; Tomimoto, H.; Wakita, H.; Yamamoto, Y.; Suenaga, T.; Ueno, M.; Budka, H.

In: Neuropathology, Vol. 19, No. 1, 08.03.1999, p. 119-128.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cytopathological alterations and therapeutic approaches in Binswanger's disease

AU - Akiguchi, I.

AU - Tomimoto, H.

AU - Wakita, H.

AU - Yamamoto, Y.

AU - Suenaga, T.

AU - Ueno, M.

AU - Budka, H.

PY - 1999/3/8

Y1 - 1999/3/8

N2 - Binswanger's disease (BD) is a condition characterized by prominent brain atrophy with ventricular dilatation, diffuse white matter (WM) lesions and a scattering of lacunar infarcts. BD patients have dementia, and have vascular risk factors, focal cerebrovascular deficits and evidence of subcortical cerebral dysfunction. From our clinical studies, the most effective prophylaxis against the development of BD is to manage the hypertension, especially a high nocturnal blood pressure, in the early stage patients showing only a scattering of lacunes and/or mild WM lesions. The pathogenesis of BD is likely to be chronic cerebral ischemia due to hypertensive small artery disease with capillary collagenosis, which causes the multiple lacunes and the alterations in the glia and axons. In addition, arterial hypertension and a subsequent dysfunction of the blood-brain barrier (BBB) may cause the WM lesions. A compromised BBB will permit the entry of serum components, immunoglobulins, complements and fibrinogen into the perivascular neural parenchyma. These substances may subsequently activate both astro- and microglia and thus damage the myelin structures. Experimentally, immunosuppressants, cyclosporin A and FK 506 suppressed both the glial activation and WM changes after chronic cerebral hypoperfusion. The prothrombotic state of the microcirculation in BD patients may also contribute to local inflammation and the BBB dysfunction, because thrombin and prostanoids are involved in various tissue reactions including brain edema and glial activation. Therefore, novel therapeutic approaches using the administration of anti-thrombin and cyclo-oxygenase-2 inhibitors as well as immunosuppressants may be useful for preventing the progression of BD.

AB - Binswanger's disease (BD) is a condition characterized by prominent brain atrophy with ventricular dilatation, diffuse white matter (WM) lesions and a scattering of lacunar infarcts. BD patients have dementia, and have vascular risk factors, focal cerebrovascular deficits and evidence of subcortical cerebral dysfunction. From our clinical studies, the most effective prophylaxis against the development of BD is to manage the hypertension, especially a high nocturnal blood pressure, in the early stage patients showing only a scattering of lacunes and/or mild WM lesions. The pathogenesis of BD is likely to be chronic cerebral ischemia due to hypertensive small artery disease with capillary collagenosis, which causes the multiple lacunes and the alterations in the glia and axons. In addition, arterial hypertension and a subsequent dysfunction of the blood-brain barrier (BBB) may cause the WM lesions. A compromised BBB will permit the entry of serum components, immunoglobulins, complements and fibrinogen into the perivascular neural parenchyma. These substances may subsequently activate both astro- and microglia and thus damage the myelin structures. Experimentally, immunosuppressants, cyclosporin A and FK 506 suppressed both the glial activation and WM changes after chronic cerebral hypoperfusion. The prothrombotic state of the microcirculation in BD patients may also contribute to local inflammation and the BBB dysfunction, because thrombin and prostanoids are involved in various tissue reactions including brain edema and glial activation. Therefore, novel therapeutic approaches using the administration of anti-thrombin and cyclo-oxygenase-2 inhibitors as well as immunosuppressants may be useful for preventing the progression of BD.

UR - http://www.scopus.com/inward/record.url?scp=0032991639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032991639&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1789.1999.00208.x

DO - 10.1046/j.1440-1789.1999.00208.x

M3 - Article

VL - 19

SP - 119

EP - 128

JO - Neuropathology

JF - Neuropathology

SN - 0919-6544

IS - 1

ER -